extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
5d95f7ea1d
commit
26c2c1bda3
5 changed files with 66 additions and 1 deletions
|
|
@ -77,6 +77,12 @@ BALANCE Model's manufacturer-funded lifestyle support requirement directly addre
|
|||
|
||||
WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
Aon data shows adherence is the binding variable for GLP-1 cost-effectiveness: adherent users (80%+) show significantly stronger outcomes across all endpoints. For diabetes patients, medical cost growth is 6 points lower at 30 months overall, but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months, but 7 points lower with consistent use. MACE reductions also scale with adherence. This confirms that the low persistence rates documented elsewhere directly undermine the economic case for GLP-1s.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
|
|||
|
||||
SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
Aon's real-world data confirms multi-organ protection extends to multiple systems: female users showed 47% MACE reduction, male users 26% reduction, plus lower rates of osteoporosis, rheumatoid arthritis, and certain pancreatic disorders. The temporal cost pattern (costs up 23% in year 1, then growth slows to 2% vs. 6% for non-users) provides the economic mechanism for how organ protection translates to cost savings—but only for long-term risk-bearers.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -315,6 +315,12 @@ The BALANCE Model is the first federal policy explicitly designed to test the pr
|
|||
|
||||
WHO's three-pillar framework mirrors the attractor state architecture: (1) creating healthier environments through population-level policies = prevention infrastructure, (2) protecting individuals at high risk = targeted intervention, (3) ensuring access to lifelong person-centered care = continuous monitoring and aligned incentives. The WHO explicitly positions GLP-1s within this comprehensive system rather than as standalone pharmacotherapy, confirming that medication effectiveness depends on embedding within structural prevention infrastructure.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
GLP-1 cost dynamics provide direct evidence for the payment alignment thesis: medical costs rise 23% in year 1 (drug costs dominate) then grow just 2% vs. 6% for non-users in year 2+ (downstream savings kick in). Short-term payers (employers with turnover) see only costs. Long-term risk-bearers (MA plans, capitated systems) capture savings. This is a concrete example of how prevention-first economics require aligned payment structures—the same intervention is inflationary or cost-saving depending solely on who bears the risk.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:set_created:2026-03-18"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-01-13
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: report
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -49,3 +53,14 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im
|
|||
EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
|
||||
|
||||
flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data
|
||||
- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users
|
||||
- After 12 months: medical costs grow 2% vs. 6% for non-users
|
||||
- Diabetes indication at 30 months: medical cost growth 6 points lower; 9 points lower with 80%+ adherence
|
||||
- Weight loss indication at 18 months: cost growth 3 points lower; 7 points lower with consistent use
|
||||
- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
|
||||
- Adherent users (80%+): 47% MACE reduction in women, 26% in men
|
||||
- Study released January 13, 2026
|
||||
|
|
|
|||
Loading…
Reference in a new issue